Experimental Drug Cuts Liver Protein Buildup in Trials
Adults with alpha-1 antitrypsin deficiency liver disease may one day have a targeted option, as a phase 3 trial continues.
Updated on Nov. 6, 2026 in Diseases — General

Pooled phase 2 analyses of fazirsiran, an experimental RNA-interference therapy, showed large reductions in liver-retained misfolded alpha-1 antitrypsin in adults with alpha-1 antitrypsin deficiency liver disease (AATD-LD). The data, from 56 patients, were presented at The Liver Meeting 2026 in Denver, Colorado, and are relevant to people living with this inherited liver condition worldwide.
Why it matters
No pharmacologic therapy is currently approved for AATD-LD, so these early results address a gap in treatment options for patients. The findings build on earlier SEQUOIA results showing that the same approach lowered serum and liver Z-AAT levels and reduced the burden of hepatic globules.
These pooled phase 2 analyses combined two randomized trials and an open-label extension involving 56 adults with AATD-LD, with follow-up of up to 196 weeks for pulmonary function. Fazirsiran 200 mg produced a median 89.6% reduction in intrahepatic Z-AAT compared with a median 25.5% increase on placebo, and liver enzymes and fibrosis scores improved relative to placebo.
The players
Pavel Strnad
Pavel Strnad is a researcher at RWTH Aachen University Hospital who presented the pooled fazirsiran analysis and whose field is liver disease, including AATD-LD.
The details
Fazirsiran is an RNA-interference therapy designed to silence the liver's production of misfolded alpha-1 antitrypsin, the protein whose accumulation drives liver injury in AATD-LD. In the studies, patients received placebo or fazirsiran at 25, 100, or 200 mg, with dosing on Day 1, at Week 4, and every 12 weeks through Week 48, and liver biopsies at specified timepoints. Treatment reduced alanine aminotransferase by a median 35.6% versus a 12.0% rise on placebo, and median METAVIR fibrosis scores fell by 1.0 point versus no change on placebo.
Timeline
November 5-9, 2026: pooled fazirsiran data presented at The Liver Meeting 2026 in Denver, Colorado.
Ongoing: a phase 3 trial evaluating fazirsiran 200 mg in AATD-LD is underway.
Health Landscape
AATD-LD currently has no approved pharmacologic therapy, so treatment has centered on managing complications rather than removing the underlying protein buildup. Fazirsiran's phase 3 trial, now in progress, will determine whether these biochemical and histologic gains translate into clinical benefit at the population level.
If you or a family member has alpha-1 antitrypsin deficiency, these results signal that a targeted therapy is under investigation, though it is not yet available. Anyone with a diagnosis or family history should discuss liver monitoring and the status of clinical trials with a hepatologist or physician.
The takeaway
Early pooled data show fazirsiran substantially lowered the misfolded protein behind AATD liver injury, a meaningful signal in a condition with no approved drug. Because these results come from small phase 2 studies, people with the condition should follow the phase 3 trial and talk with their doctor about liver health monitoring.
What happens next
A phase 3 trial of fazirsiran 200 mg in AATD-LD is ongoing, and its results will be the next major test of whether these findings hold in a larger population.
Further reading
For broader background, explore our Diseases — General coverage.
Source note: This article includes information reported by Hcplive.


